|Bone marrow smear from a child with Down syndrome who suffers from leukemia. The purple-colored leukemic blasts displace normal blood formation. |
Photo Credit: Jan Klusmann, University Hospital Frankfurt
People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukemia (AML), an aggressive form of blood cancer. Scientists led by the Department of Pediatrics at University Hospital Frankfurt have now identified the cause: although the additional chromosome 21 leads to increased gene dosage of many genes, it is above all the perturbation of the RUNX1 gene – a gene that regulates many other genes – that seems to be responsible for AML pathogenesis. Targeting the perturbed regulator could pave the way for new therapies.
Leukemia (blood cancer) is a group of malignant and aggressive diseases of the blood-forming cells in the bone marrow. Very intensive chemotherapy and in some cases a bone marrow transplant are the only cure. Like all cancers, leukemia is caused by changes in the DNA, the heredity material present in human cells in the form of 46 chromosomes. In many forms of leukemia, large parts of these chromosomes are altered. People with Down syndrome, who have three copies of chromosome 21 (trisomy 21), are highly vulnerable: the risk of developing aggressive Acute Myeloid Leukemia (AML) in the first four years of their life is more than 100 times greater for children with Down syndrome. Down syndrome is the most common congenital genetic disorder, affecting about one in 700 newborn babies.
The research group led by Professor Jan-Henning Klusmann, Director of the Department of Pediatric and Adolescent Medicine at University Hospital Frankfurt, has now discovered how the additional chromosome 21 can promote AML. With the help of genetic scissors (CRISPR-Cas9), they examined each of the 218 genes on chromosome 21 for its carcinogenic effect. It emerged that the RUNX1 gene is responsible for the chromosome's specific carcinogenic properties. In further analyses, the researchers were able to corroborate that only one particular variant – or isoform – of the gene promotes the development of leukemia. Klusmann explains: “Other RUNX1 isoforms were even able to prevent the cells from degenerating. This explains why RUNX1 has so far not stood out – in several decades of extensive cancer research."
The RUNX1 gene encodes a “transcription factor" – a protein responsible for regulating the activity of other genes. RUNX1 regulates many processes, including embryonic development and early and late hematopoiesis, or blood formation. Disruption of this important regulator is therefore a key event in the development of AML. “Thanks to our research results, we now have a better understanding of what happens in leukemogenesis," explains Klusmann, an expert in pediatric cancer. “The study underlines how important it is to examine all gene variants in carcinogenesis. In many cases, certain mutations in cancer cells alter how these variants form," he says.
Development of more sophisticated therapeutic approaches
These insights are important for a better understanding of the complex mechanisms of carcinogenesis, as Klusmann explains: “In this way, we have laid the groundwork for developing more sophisticated therapeutic approaches. Through our biochemical analyses, we now know exactly how the gene variant alters the blood cells. From there, we were able to use specific substances that block the disease mechanism." The intention now is to further explore the effect of these substances for use in medical care. Klusmann: “On the basis of our expertise, we now want to develop therapies to correct this malfunction. Applying them in clinical practice will certainly take a few more years, but hopefully they will lead in the future to sparing our young patients from intensive chemotherapy."
Published in journal: Journal Blood
Source/Credit: Goethe University | Susanne Clara Bard
Reference Number: med031223_02